Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

NCT03630315 is registered in ClinicalTrials.gov with Ocular Therapeutix, Inc. as lead sponsor.

NCT NCT03630315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03630315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Lead sponsor
Ocular Therapeutix, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 18, 2019
Completion date
January 10, 2024
Enrollment
29 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration